Saturday Rounds: Week of August 29–September 4, 2026

Six approvals, a pivotal cardiovascular-outcomes miss, two paused autoimmune cell-therapy programs, and roughly $6.9 billion of headline dealmaking — this week’s signals only counted once verified against a primary source. Weekly Biotech Signal Review · Week of August 29–September 4, 2026 · Published September 5,…